News

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
That's what happened beginning in November of last year, anyway. The company announced solid testing results for VK2735. But ...
ScoPo’s Powerplays: CSL leads a 5pc ASX health stocks rally
Morgans healthcare and life sciences expert Iain Wilkie fills in for Scott Power this week, covering what the health movers ...
KFF Health News22h
From KFF Health News - Latest Stories:
The agreement, signed Monday between CMS and DHS, has not been announced publicly, AP reports. Other Trump administration ...
Why Eli Lilly (LLY) is Emerging as a Dividend Growth Leader in Pharma for 2025
Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. In the past five years, the company has raised its payouts at an annual average rate of 16%. Its ...
FDA rejects Genentec's cancer drug label expansion
Genentech, part of the Roche Group ( OTCQX:RHHBY) ( OTCQX:RHHBF) ( OTCPK:RHHVF ), announced that the U.S. FDA has rejected ...
Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths
The regulator had asked Sarepta Therapeutics to halt all shipments of its therapy, Ele­vidys, after three patients died from ...
Fierce Pharma18h
FDA rejects Roche's Columvi in earlier diffuse large B-cell lymphoma, citing lackluster US data
The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...
Lymphoma Treatment Market to Surpass USD 14.66 Billion by 2032, Fueled by Immunotherapy Advancements and Emerging Market Expansion - SNS Insider
U.S. Market Leads with 74% Share in 2023 Valued at USD 2.71 Billion, Driven by Biotech Innovation, Favorable FDA Approvals, and Rising Chronic Disease Incidence.Austin, July 18, 2025 (GLOBE NEWSWIRE) ...